Close Menu

NEW YORK – SkylineDx said this week that it has inked a 10th collaboration agreement with an academic partner under its Falcon R&D Program to enable further validation of its Merlin and Peregrine melanoma tests. The collaboration with 10 clinical centers, located in six countries, will allow SkylineDx to use data from more than 3,500 patients with cutaneous melanoma, the firm said.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.